首页> 外文OA文献 >Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study

【2h】

Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study

机译：Neoadjuvant叶氏素释放激素激素激动剂加上低剂量雌激素磷酸盐的安全性和有效性，高危前列腺癌：一项潜在的单臂研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
T Koie; C Ohyama; H Yamamoto; S Hatakeyama; T Yoneyama; Y Hashimoto; N Kamimura;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study [J] . T Koie, C Ohyama, H Yamamoto, Prostate Cancer and Prostatic Diseases . 2012,第4期

机译：新辅助黄体生成激素释放激素激动剂加小剂量雌莫司汀磷酸盐在高危前列腺癌中的安全性和有效性：前瞻性单臂研究
2. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis [J] . Koie Takuya, Mitsuzuka Koji, Yoneyama Takahiro, International journal of clinical oncology . 2015,第5期

机译：新辅助黄体激素释放激素激动剂加小剂量雌莫司汀磷酸盐可改善高危前列腺癌患者的前列腺特异性无抗原生存率：倾向得分匹配分析
3. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. [J] . Noguchi M, Noda S, Yoshida M, International journal of urology: official journal of the Japanese Urological Association . 2004,第2期

机译：化学激素疗法是转移性前列腺癌的主要治疗方法：一项随机研究：雌莫司汀磷酸盐加促黄体激素释放激素激动剂与氟他胺加促黄体激素释放激素激动剂。
4. Synthesis and structural studies of new analogues of the decapeptide Luteinizing Hormone-Releasing Hormone (LHRH) [C] . Aikaterini A.Zompra, Dimitris Vachliotis, Georgios A.Spyroulias, European Peptide Symposium . 2002

机译：疏皮肽丁骨释放激素（LHRH）新型类似物的合成与结构研究
5. Changes in bone mineral density in men with prostate cancer during treatment with luteinizing hormone-releasing hormone (LHRH) agonist monotherapy. [D] . Conde, Francisco Alcasid, II. 2003

机译：黄体激素释放激素（LHRH）激动剂单药治疗期间前列腺癌男性的骨矿物质密度变化。
6. Selection criteria for initiation and renewal of luteinizing hormone-releasing hormone agonist therapy in patients with prostate cancer: a French prospective observational study [O] . Thierry Lebret, Jean-Louis Davin, Christophe Hennequin, 2014

机译：前列腺癌患者黄体生成激素释放激素激动剂治疗的启动和更新选择标准：一项法国前瞻性观察性研究
7. Both radical prostatectomy following treatment with neoadjuvant LHRH agonist and estramustine and radiotherapy following treatment with neoadjuvant hormonal therapy achieved favorable oncological outcome in high-risk prostate cancer: a propensity-score matching analysis [O] . Takuya Koie, Chikara Ohyama, Hayato Yamamoto, 2014

机译：新辅助LHRH激动剂和雌莫司汀进行的根治性前列腺切除术以及新辅助激素治疗后的放射疗法在高危前列腺癌中均取得了良好的肿瘤学结局：倾向评分匹配分析

Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study

著录项

相似文献

相关主题

期刊订阅